Skip to Main Content

Clinical Studies and Protocols

Site Map Investigators Log-in
(RDA-0537) Dendritic cell vaccine (DC/PC3) for prostate cancer

 Return to List of Clinical Studies
 Return to List of Protocols for Cancer
A Phase I/II Study of Autologous Dendritic Cells Pulsed with Apoptotic Tumor Cells (DC/PC3) Administered Subcutaneously to Prostate cancer Patients (RDA-0537)

Principal Investigator:
Robert B. Darnell M.D., Ph.D.


Contact Information:
Mayu Frank, ANP
Rockefeller University
1230 York Avenue
New York, NY 10065
Telephone: 212-327-7443
Enrollment Status:
Closed to Enrollment

Brief Summary of Protocol:
This is a dendritic cell vaccine study for prostate cancer patients. Vaccine will be made from each individual participant’s white blood cells. Patients will receive vaccine and 3 boosters every 2 weeks in hopes of boosting the immune system against the patient’s own cancer cells. This is an outpatient study.

Detailed Description of Protocol:

What specifically makes a person eligible for the study?
You may be eligible to enter this study:

Diagnosis of prostate cancer

Rising PSA after definitive local therapy or with hormone therapy

No neurologic metastasis

No history of autoimmune diseases

HLA A2.1 positive


18 years and older

Children permitted to participate:

Potential Benefits.....
As this is a phase I/II study, there are no known benefits as of yet.